158 related articles for article (PubMed ID: 17712824)
1. Fatty acid amide hydrolase: from characterization to therapeutics.
Labar G; Michaux C
Chem Biodivers; 2007 Aug; 4(8):1882-902. PubMed ID: 17712824
[TBL] [Abstract][Full Text] [Related]
2. Fatty acid amide hydrolase: a gate-keeper of the endocannabinoid system.
Fezza F; De Simone C; Amadio D; Maccarrone M
Subcell Biochem; 2008; 49():101-32. PubMed ID: 18751909
[TBL] [Abstract][Full Text] [Related]
3. Pain and beyond: fatty acid amides and fatty acid amide hydrolase inhibitors in cardiovascular and metabolic diseases.
Pillarisetti S; Alexander CW; Khanna I
Drug Discov Today; 2009 Dec; 14(23-24):1098-111. PubMed ID: 19716430
[TBL] [Abstract][Full Text] [Related]
4. A second fatty acid amide hydrolase with variable distribution among placental mammals.
Wei BQ; Mikkelsen TS; McKinney MK; Lander ES; Cravatt BF
J Biol Chem; 2006 Dec; 281(48):36569-78. PubMed ID: 17015445
[TBL] [Abstract][Full Text] [Related]
5. Structure and function of fatty acid amide hydrolase.
McKinney MK; Cravatt BF
Annu Rev Biochem; 2005; 74():411-32. PubMed ID: 15952893
[TBL] [Abstract][Full Text] [Related]
6. Selective inhibitors of fatty acid amide hydrolase relative to neuropathy target esterase and acetylcholinesterase: toxicological implications.
Quistad GB; Sparks SE; Segall Y; Nomura DK; Casida JE
Toxicol Appl Pharmacol; 2002 Feb; 179(1):57-63. PubMed ID: 11884237
[TBL] [Abstract][Full Text] [Related]
7. Latest advances in the discovery of fatty acid amide hydrolase inhibitors.
Bisogno T; Maccarrone M
Expert Opin Drug Discov; 2013 May; 8(5):509-22. PubMed ID: 23488865
[TBL] [Abstract][Full Text] [Related]
8. Cyclohexylcarbamic acid 3'- or 4'-substituted biphenyl-3-yl esters as fatty acid amide hydrolase inhibitors: synthesis, quantitative structure-activity relationships, and molecular modeling studies.
Mor M; Rivara S; Lodola A; Plazzi PV; Tarzia G; Duranti A; Tontini A; Piersanti G; Kathuria S; Piomelli D
J Med Chem; 2004 Oct; 47(21):4998-5008. PubMed ID: 15456244
[TBL] [Abstract][Full Text] [Related]
9. Oxime carbamate--discovery of a series of novel FAAH inhibitors.
Sit SY; Conway CM; Xie K; Bertekap R; Bourin C; Burris KD
Bioorg Med Chem Lett; 2010 Feb; 20(3):1272-7. PubMed ID: 20036536
[TBL] [Abstract][Full Text] [Related]
10. Enol carbamates as inhibitors of fatty acid amide hydrolase (FAAH) endowed with high selectivity for FAAH over the other targets of the endocannabinoid system.
Gattinoni S; De Simone C; Dallavalle S; Fezza F; Nannei R; Amadio D; Minetti P; Quattrociocchi G; Caprioli A; Borsini F; Cabri W; Penco S; Merlini L; Maccarrone M
ChemMedChem; 2010 Mar; 5(3):357-60. PubMed ID: 20112328
[No Abstract] [Full Text] [Related]
11. Therapeutic potential of endocannabinoid-hydrolysing enzyme inhibitors.
Saario SM; Laitinen JT
Basic Clin Pharmacol Toxicol; 2007 Nov; 101(5):287-93. PubMed ID: 17910610
[TBL] [Abstract][Full Text] [Related]
12. Nuclear localisation of the endocannabinoid metabolizing enzyme fatty acid amide hydrolase (FAAH) in invasive trophoblasts and an association with recurrent miscarriage.
Chamley LW; Bhalla A; Stone PR; Liddell H; O'Carroll S; Kearn C; Glass M
Placenta; 2008 Nov; 29(11):970-5. PubMed ID: 18805581
[TBL] [Abstract][Full Text] [Related]
13. High-throughput screening for the discovery of inhibitors of fatty acid amide hydrolase using a microsome-based fluorescent assay.
Wang Y; Ramirez F; Krishnamurthy G; Gilbert A; Kadakia N; Xu J; Kalgaonkar G; Ramarao MK; Edris W; Rogers KE; Jones PG
J Biomol Screen; 2006 Aug; 11(5):519-27. PubMed ID: 16760367
[TBL] [Abstract][Full Text] [Related]
14. QM/MM modelling of oleamide hydrolysis in fatty acid amide hydrolase (FAAH) reveals a new mechanism of nucleophile activation.
Lodola A; Mor M; Hermann JC; Tarzia G; Piomelli D; Mulholland AJ
Chem Commun (Camb); 2005 Sep; (35):4399-401. PubMed ID: 16136230
[TBL] [Abstract][Full Text] [Related]
15. Membrane lipids are key modulators of the endocannabinoid-hydrolase FAAH.
Dainese E; De Fabritiis G; Sabatucci A; Oddi S; Angelucci CB; Di Pancrazio C; Giorgino T; Stanley N; Del Carlo M; Cravatt BF; Maccarrone M
Biochem J; 2014 Feb; 457(3):463-72. PubMed ID: 24215562
[TBL] [Abstract][Full Text] [Related]
16. The endocannabinoid system: current pharmacological research and therapeutic possibilities.
Jonsson KO; Holt S; Fowler CJ
Basic Clin Pharmacol Toxicol; 2006 Feb; 98(2):124-34. PubMed ID: 16445584
[TBL] [Abstract][Full Text] [Related]
17. Elucidation of hydrolysis mechanisms for fatty acid amide hydrolase and its Lys142Ala variant via QM/MM simulations.
Tubert-Brohman I; Acevedo O; Jorgensen WL
J Am Chem Soc; 2006 Dec; 128(51):16904-13. PubMed ID: 17177441
[TBL] [Abstract][Full Text] [Related]
18. A new group of oxime carbamates as reversible inhibitors of fatty acid amide hydrolase.
Gattinoni S; Simone CD; Dallavalle S; Fezza F; Nannei R; Battista N; Minetti P; Quattrociocchi G; Caprioli A; Borsini F; Cabri W; Penco S; Merlini L; Maccarrone M
Bioorg Med Chem Lett; 2010 Aug; 20(15):4406-11. PubMed ID: 20591666
[TBL] [Abstract][Full Text] [Related]
19. Mining biologically-active molecules for inhibitors of fatty acid amide hydrolase (FAAH): identification of phenmedipham and amperozide as FAAH inhibitors.
Vincent F; Nguyen MT; Emerling DE; Kelly MG; Duncton MA
Bioorg Med Chem Lett; 2009 Dec; 19(23):6793-6. PubMed ID: 19850474
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of fatty acid amide hydrolase and cyclooxygenase-2 increases levels of endocannabinoid related molecules and produces analgesia via peroxisome proliferator-activated receptor-alpha in a model of inflammatory pain.
Jhaveri MD; Richardson D; Robinson I; Garle MJ; Patel A; Sun Y; Sagar DR; Bennett AJ; Alexander SP; Kendall DA; Barrett DA; Chapman V
Neuropharmacology; 2008 Jul; 55(1):85-93. PubMed ID: 18534634
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
